STX — Shield Therapeutics Share News
0.000.00%
Last trade - 00:00- £26.82m
- £41.50m
- $32.18m
- 25
- 24
- 43
- 17
REG - Shield Therapeutics - Audited results for the year ended 31 Dec 2024
AnnouncementREG - Shield Therapeutics - Licence Agreement in Japan for ACCRUFeR®
AnnouncementREG - Shield Therapeutics - Q1 2025 Trading Update
AnnouncementREG - Shield Therapeutics - ACCRUFeR® launched in Canada
AnnouncementREG - Shield Therapeutics - PDMR Transaction Notification
AnnouncementREG - Shield Therapeutics - Grant of Share Options
AnnouncementREG - Shield Therapeutics - Unaudited full year trading update
AnnouncementREG - Shield Therapeutics - Anders Lundstrom appointed CEO
AnnouncementREG - AIM - AIM Notice - 30/12/2024
AnnouncementREG - Shield Therapeutics - Result of General Meeting & Total Voting Rights
AnnouncementREG - Shield Therapeutics - Results of RetailBook Offer
AnnouncementREG - Shield Therapeutics - RetailBook Offer
AnnouncementREG - Shield Therapeutics - Subscription by AOP Health to raise US$10 million
AnnouncementREG - Shield Therapeutics - Business Update
AnnouncementREG - Shield Therapeutics - Q3 Trading Update
AnnouncementREG - Shield Therapeutics - Results from Phase 3 paediatric study
AnnouncementREG - Shield Therapeutics - Interim results
AnnouncementREG - Shield Therapeutics - ACCRUFeR® Approved by Health Canada
AnnouncementREG - Shield Therapeutics - Notice of interim results
Announcement